C-Met Modulators and Methods of Use
US-2015376133-A1 · Dec 31, 2015 · US
Crystalline erlotinib hydrochloride process
US9593083B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9593083-B2 |
| Application number | US-201314418449-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 14, 2013 |
| Priority date | Sep 4, 2012 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2θ° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2θ°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak −1) and 225 to 235° C. (Peak −2) and IR absorption characteristic peaks at approximately 3278 cm −1 , 1948 cm −1 , 1871 cm −1 , 1632 cm −1 , 1164 cm −1 , 1024 cm −1 , 940 cm −1 and 742 cm −1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.
First claim
Opening claim text (preview).
We claim: 1. Erlotinib hydrochloride (I) crystalline Form-SE characterized by X-ray powder diffraction pattern according to FIG.- 1 .
Assignees
Inventors
Classifications
- C07D239/94Primary
Nitrogen atoms · CPC title
Crystalline forms, e.g. polymorphs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9593083B2 cover?
- The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2θ° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2θ°, DSC isotherm comprising the endotherm…
- Who is the assignee on this patent?
- Shilpa Medicare Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D239/94. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).